TrxR-IN-9
TrxR-IN-9 is a thioredoxin reductase (TrxR) inhibitor with an IC50 of 0.26 μM. TrxR-IN-9 disrupts cellular redox balance. TrxR-IN-9 induces S-phase cell cycle arrest, promotes apoptosis and exhibits antiproliferative activity across cancer cells. TrxR-IN-9 exerts effects via synergistic nitric oxide (NO) and reactive oxygen species (ROS) action. TrxR-IN-9 can be used for the research of breast cancer, gastric cancer, colorectal cancer, liver cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C20H21N3O9
- Masse moléculaire:447.40
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
TrxR-IN-9 (11f) potently inhibits purified TrxR with an IC50 of 0.26 μM[1].
TrxR-IN-9 (10 μM; 48 h) selectively inhibits the proliferation of BGC823, HCT116, Hep G2, and MCF-7 cancer cells with IC50 values ranging from 0.32 to 1.5 μM, while showing minimal cytotoxicity to normal NIH-3T3 fibroblasts (IC50 > 50 μM)[1].
TrxR-IN-9 (0.1-2.0 μM; 48 h) inhibits TrxR activity in MCF-7 cells in a concentration-dependent manner with an IC50 of 0.33 μM[1].
TrxR-IN-9 (0.1-1 μM; 6 h) induces concentration-dependent intracellular ROS accumulation in MCF-7 cells[1].
TrxR-IN-9 (0.1-1 μM; 24 h) induces dose-dependent apoptosis in MCF-7 cells[1].
TrxR-IN-9 (0.1-1 μM; 36 h) induces concentration-dependent S-phase cell cycle arrest in MCF-7 cells[1].
TrxR-IN-9 (200 min) releases high levels of NO, which correlates with its anticancer cytotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7 breast cancer cells
-
Concentration:0.1, 0.5, 1 μM
-
Incubation Time:24 h
-
Result:Increased the number of cells with condensed apoptotic nuclei in a concentration-dependent manner.
Induced dose-dependent apoptotic cell death, with significantly elevated early and late apoptosis rates at higher concentrations.
-
Cell Line:MCF-7 breast cancer cells
-
Concentration:0.1, 0.5, 1 μM
-
Incubation Time:36 h
-
Result:Induced concentration-dependent S-phase arrest, with the percentage of cells in S phase increasing from 35.62% (control) to 43.20% at 1 μM, concurrent with decreases in G0/G1 and G2/M phase populations.
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Flow cytometric DNA-content cell-cycle staining
- Annexin V plus membrane-impermeant dye apoptosis staining
- ROS/oxidative-stress fluorescent staining
- BrdU Incorporation Assay
- Apoptosis Solutions
- Protocol for Cell Cycle
- Liver Cancer Modeling
- Breast Cancer Modeling
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
Masse moléculaire 447.40
-
Formule C20H21N3O9
-
SMILES
O=C(C1=CC=C(OCCCO[N+]([O-])=O)C=C1OCCCO[N+]([O-])=O)/C=C/C2=NC=CC=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TrxR-IN-9 Related Classifications
HY-181825 Related Classifications
Powered by Bioz